Metastatic Melanoma Clinical Trial
Official title:
Phase III Trial of Salvage Stereotactic Radiosurgery (SRS) or SRS + Hippocampal-Avoidant Whole Brain Radiotherapy (HA-WBRT) for First or Second Distant Brain Relapse After Upfront SRS With Brain Metastasis Velocity >/= 4 Brain Metastases/Year
Verified date | January 2024 |
Source | NRG Oncology |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This phase III trial compares the effect of adding whole brain radiotherapy with hippocampal avoidance and memantine to stereotactic radiosurgery versus stereotactic radiosurgery alone in treating patients with cancer that has spread to the brain and come back in other areas of the brain after earlier stereotactic radiosurgery. Hippocampus avoidance during whole-brain radiation therapy decreases the amount of radiation that is delivered to the hippocampus, which is a brain structure that is important for memory. The medicine memantine is also often given with whole brain radiation therapy because it may decrease the risk of side effects of radiation on thinking and memory. Stereotactic radiosurgery delivers a high dose of radiation only to the small areas of cancer in the brain and avoids the surrounding normal brain tissue. Adding whole brain radiotherapy with hippocampal avoidance and memantine to stereotactic radiosurgery may be effective in shrinking or stabilizing cancer that has spread to the brain and returned in other areas of the brain after receiving stereotactic radiosurgery.
Status | Recruiting |
Enrollment | 350 |
Est. completion date | January 31, 2030 |
Est. primary completion date | January 31, 2025 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Patients must have developed their first or second distant brain relapse(s) at least 8 weeks after upfront SRS and within 21 days prior to randomization - Distant brain relapse lesions to be treated must measure =< 3.0 cm in maximal extent and total volume of distant brain relapses to be treated must measure < 30 mL on the contrast-enhanced diagnostic magnetic resonance imaging (MRI) brain scan obtained within 21 days prior to randomization - Distant brain relapse lesions must be diagnosed on MRI, which will include the following elements: - REQUIRED MRI ELEMENTS - Post gadolinium contrast-enhanced T1-weighted three-dimensional (3D) spoiled gradient (SPGR). Acceptable 3D SPGR sequences include magnetization-prepared 3D gradient recalled echo (GRE) rapid gradient echo (MP-RAGE), turbo field echo (TFE) MRI, BRAVO (brain volume imaging) or 3D fast FE (field echo). The T1-weighted 3D scan should use the smallest possible axial slice thickness, not to exceed 1.5 mm - Pre-contrast T1 weighted imaging (3D imaging sequence strongly encouraged) - A minimum of one axial T2 fluid attenuated inversion recovery (FLAIR) (preferred) or T2 sequence is required. This can be acquired as a 2D or 3D image. If 2D, the images should be obtained in the axial plane - ADDITIONAL RECOMMENDATIONS - Recommendation is that an axial T2 FLAIR (preferred) sequence be performed instead of a T2 sequence - Recommendation is that that pre-contrast 3D T1 be performed with the same parameters as the post-contrast 3D T1 - Recommendation is that imaging be performed on a 3 Tesla (3T) MRI - Recommendation is that the study participants be scanned on the same MRI instrument at each time point - Recommendation is that if additional sequences are obtained, these should meet the criteria outlined in Kaufmann et al., 2020 - If additional sequences are obtained, total imaging time should not exceed 60 minutes - Brain metastasis velocity (BMV) since upfront SRS must be >= 4 brain metastases/year - The patient or a legally authorized representative must provide study-specific informed consent prior to study entry - Pathologically (histologically or cytologically) proven diagnosis of non-small cell lung cancer, melanoma, breast cancer, renal cell carcinoma, or gastrointestinal cancer within 10 years prior to randomization. If the original histologic proof of malignancy is greater than 10 years, then pathological (i.e., more recent) confirmation is required (e.g., from a systemic metastasis or brain metastasis) - Other histologies are not permitted - History and physical examination within 28 days prior to randomization - Karnofsky performance status of >= 70 within 28 days prior to randomization - Calculated creatinine clearance (CrCl) >= 30 ml/min (within 28 days prior to randomization) - Blood urea nitrogen (BUN) within 1.5 times the institutional upper limit of normal (ULN) (e.g., if the ULN is 20 mg/dL, then BUN up to 30 mg/dL is permitted) (within 28 days prior to randomization) - Negative urine or serum pregnancy test (in women of childbearing potential) within 14 days prior to randomization Exclusion Criteria: - Prior WBRT or prophylactic cranial irradiation - Local relapse of metastasis previously treated with upfront SRS (i.e., relapse outside previously SRS-treated metastases is allowed) - Brain metastases from primary germ cell tumor, small cell carcinoma, or lymphoma - Definitive leptomeningeal metastasis - Planned cytotoxic chemotherapy on the same day as SRS or HA-WBRT; concurrent immunotherapy is permitted - Radiographic evidence of enlargement or other architectural distortion of the lateral ventricles, including placement of external ventricular drain or ventriculoperitoneal shunt - Known history of demyelinating disease such as multiple sclerosis - Inability to swallow pills - Contraindication to MR imaging such as non-MR conditional implanted metal devices or unknown metallic foreign bodies, or contraindication to gadolinium contrast administration during MR imaging, such as anaphylactic allergy that cannot be adequately addressed with pre-contrast medications or acute kidney injury - Contraindications to memantine, including: - Allergy, including prior allergic reaction to memantine - Intractable seizures on adequate anticonvulsive therapy-more than 1 seizure per month for the past 2 months - Current use of N-methyl-D-aspartate (NMDA) agonist - Current alcohol or drug abuse, which can exacerbate lethargy/dizziness with memantine - Severe, active co-morbidity defined as follows: - Unstable angina and/or congestive heart failure requiring hospitalization within the last 6 months - Transmural myocardial infarction within the last 6 months - Acute bacterial or fungal infection requiring intravenous antibiotics at the time of randomization - Chronic obstructive pulmonary disease exacerbation or other acute respiratory illness precluding study therapy at the time of randomization - Severe hepatic disease defined as a diagnosis of Child-Pugh class B or C hepatic disease - Renal tubular acidosis or metabolic acidosis - Human immunodeficiency virus (HIV) positive with CD4 count < 200 cells/microliter. Note that patients who are HIV positive are eligible, provided they are under treatment with highly active antiretroviral therapy (HAART) and have a CD4 count >= 200 cells/microliter within 30 days prior to randomization. Note also that HIV testing is not required for eligibility for this protocol - Pregnant or lactating women, or women of childbearing potential and men who are sexually active and not willing/able to use medically acceptable forms of contraception; this exclusion is necessary because the medication and radiation involved in this study has unknown effects on the unborn fetus |
Country | Name | City | State |
---|---|---|---|
United States | Saint Joseph Mercy Hospital | Ann Arbor | Michigan |
United States | MedStar Franklin Square Medical Center/Weinberg Cancer Institute | Baltimore | Maryland |
United States | University of Maryland/Greenebaum Cancer Center | Baltimore | Maryland |
United States | UM Upper Chesapeake Medical Center | Bel Air | Maryland |
United States | Sanford Bismarck Medical Center | Bismarck | North Dakota |
United States | Tufts Medical Center | Boston | Massachusetts |
United States | Trinity Health IHA Medical Group Hematology Oncology - Brighton | Brighton | Michigan |
United States | Christiana Care Health System-Concord Health Center | Chadds Ford | Pennsylvania |
United States | Medical University of South Carolina | Charleston | South Carolina |
United States | Saint Joseph Mercy Chelsea | Chelsea | Michigan |
United States | Trinity Health IHA Medical Group Hematology Oncology - Chelsea Hospital | Chelsea | Michigan |
United States | Northwestern University | Chicago | Illinois |
United States | Rush University Medical Center | Chicago | Illinois |
United States | University of Chicago Comprehensive Cancer Center | Chicago | Illinois |
United States | Central Maryland Radiation Oncology in Howard County | Columbia | Maryland |
United States | Ohio State University Comprehensive Cancer Center | Columbus | Ohio |
United States | UM Sylvester Comprehensive Cancer Center at Coral Gables | Coral Gables | Florida |
United States | City of Hope Corona | Corona | California |
United States | Siteman Cancer Center at West County Hospital | Creve Coeur | Missouri |
United States | Carle at The Riverfront | Danville | Illinois |
United States | Geisinger Medical Center | Danville | Pennsylvania |
United States | UM Sylvester Comprehensive Cancer Center at Deerfield Beach | Deerfield Beach | Florida |
United States | Northwestern Medicine Cancer Center Kishwaukee | DeKalb | Illinois |
United States | City of Hope Comprehensive Cancer Center | Duarte | California |
United States | Carle Physician Group-Effingham | Effingham | Illinois |
United States | Sanford Broadway Medical Center | Fargo | North Dakota |
United States | Sanford Roger Maris Cancer Center | Fargo | North Dakota |
United States | Northwestern Medicine Cancer Center Delnor | Geneva | Illinois |
United States | UM Baltimore Washington Medical Center/Tate Cancer Center | Glen Burnie | Maryland |
United States | UPMC Cancer Centers - Arnold Palmer Pavilion | Greensburg | Pennsylvania |
United States | Prisma Health Cancer Institute - Faris | Greenville | South Carolina |
United States | City of Hope at Irvine Lennar | Irvine | California |
United States | University of Mississippi Medical Center | Jackson | Mississippi |
United States | Mayo Clinic in Florida | Jacksonville | Florida |
United States | Northwell Health/Center for Advanced Medicine | Lake Success | New York |
United States | City of Hope Antelope Valley | Lancaster | California |
United States | Geisinger Medical Oncology-Lewisburg | Lewisburg | Pennsylvania |
United States | Covenant Medical Center-Lakeside | Lubbock | Texas |
United States | University of Wisconsin Carbone Cancer Center | Madison | Wisconsin |
United States | Carle Physician Group-Mattoon/Charleston | Mattoon | Illinois |
United States | Riddle Memorial Hospital | Media | Pennsylvania |
United States | Froedtert Menomonee Falls Hospital | Menomonee Falls | Wisconsin |
United States | University of Miami Miller School of Medicine-Sylvester Cancer Center | Miami | Florida |
United States | Medical College of Wisconsin | Milwaukee | Wisconsin |
United States | West Virginia University Healthcare | Morgantown | West Virginia |
United States | Christiana Care Health System-Christiana Hospital | Newark | Delaware |
United States | Delaware Clinical and Laboratory Physicians PA | Newark | Delaware |
United States | Helen F Graham Cancer Center | Newark | Delaware |
United States | Medical Oncology Hematology Consultants PA | Newark | Delaware |
United States | Drexel Town Square Health Center | Oak Creek | Wisconsin |
United States | University of Oklahoma Health Sciences Center | Oklahoma City | Oklahoma |
United States | Memorial Hospital West | Pembroke Pines | Florida |
United States | Thomas Jefferson University Hospital | Philadelphia | Pennsylvania |
United States | UPMC-Shadyside Hospital | Pittsburgh | Pennsylvania |
United States | Geisinger Cancer Services-Pottsville | Pottsville | Pennsylvania |
United States | Virginia Commonwealth University/Massey Cancer Center | Richmond | Virginia |
United States | University of Rochester | Rochester | New York |
United States | Sutter Cancer Centers Radiation Oncology Services-Roseville | Roseville | California |
United States | Sutter Roseville Medical Center | Roseville | California |
United States | Sutter Medical Center Sacramento | Sacramento | California |
United States | Siteman Cancer Center at Christian Hospital | Saint Louis | Missouri |
United States | Siteman Cancer Center-South County | Saint Louis | Missouri |
United States | Washington University School of Medicine | Saint Louis | Missouri |
United States | Siteman Cancer Center at Saint Peters Hospital | Saint Peters | Missouri |
United States | City of Hope South Pasadena | South Pasadena | California |
United States | City of Hope South Bay | Torrance | California |
United States | Banner University Medical Center - Tucson | Tucson | Arizona |
United States | University of Arizona Cancer Center-North Campus | Tucson | Arizona |
United States | City of Hope Upland | Upland | California |
United States | Carle Cancer Center | Urbana | Illinois |
United States | The Carle Foundation Hospital | Urbana | Illinois |
United States | Northwestern Medicine Cancer Center Warrenville | Warrenville | Illinois |
United States | Froedtert West Bend Hospital/Kraemer Cancer Center | West Bend | Wisconsin |
United States | Asplundh Cancer Pavilion | Willow Grove | Pennsylvania |
United States | Wake Forest University Health Sciences | Winston-Salem | North Carolina |
United States | Lankenau Medical Center | Wynnewood | Pennsylvania |
United States | UPMC Memorial | York | Pennsylvania |
United States | Trinity Health IHA Medical Group Hematology Oncology Ann Arbor Campus | Ypsilanti | Michigan |
Lead Sponsor | Collaborator |
---|---|
NRG Oncology | National Cancer Institute (NCI) |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Time to Neurologic Death | The primary comparison of treatment effect on neurologic deaths will be based a one-sided 0.05-level (score) test for cause-specific hazard ratio in a Cox proportional hazards model. Additional analyses will involve estimating the median time to neurologic death using the cumulative incidence function estimator in the presence of precluding events such as non-neurologic deaths in the two arms, separately. The Gray's test will be used to evaluate the difference in the distribution of neurologic deaths. These results will be interpreted in light of the competing non-neurologic deaths, which may be frequent. | From randomization until progressive neurologic decline at time of death, irrespective of status of extracranial disease, or death from inter-current disease in patients with severe neurologic dysfunction, assessed up to 3 years | |
Secondary | Overall Survival (OS) | Analysis will consist of estimation of the OS curves via the Kaplan-Meier method and a stratified log-rank test. Additional analyses may consist of estimating the hazard ratio via the Cox proportional hazards model, accounting for other prognostic covariates (and evaluating whether the proportional hazards assumption holds or whether any treatment effect is notably time-varying), and evaluating for potential treatment by prognostic covariate interactions. | From randomization to death from any cause, assessed up to 3 years | |
Secondary | Intracranial Progression-Free Survival (IPFS) | Analysis will consist of estimation of the IPFS curves via the Kaplan-Meier method and a stratified log-rank test. Additional analyses may consist of estimating the hazard ratio via the Cox proportional hazards model, accounting for other prognostic covariates (and evaluating whether the proportional hazards assumption holds or whether any treatment effect is notably time-varying), and evaluating for potential treatment by prognostic covariate interactions. | From randomization to intracranial progression or death from any cause, assessed up to 3 years | |
Secondary | Brain Metastasis Velocity (BMV) at subsequent relapse | The Wilcoxon rank-sum test will be used to compare the distributions of BMVs between the two treatment arms at 2-sided 0.05 level. | Up to 3 years | |
Secondary | Cognitive Abilities | Measured by the Patient Reported Outcomes Measurement Information System Cognitive Function Short Form 4a version 2.0. | Up to 1 year | |
Secondary | Symptom Burden | Measured by the MD Anderson Symptom Inventory - Brain Tumor (MDASI-BT). The MDASI-BT rates symptoms on an 11- point scale (0 to 10) to indicate the presence and severity of the symptom, with 0 being "not present" and 10 being "as bad as you can imagine." Each symptom is rated at its worst in the last 24 hours. | Up to 1 year | |
Secondary | Health Status | Measured by the European Quality of Life Five Dimension Five Level Scale Questionnaire (EQ-5D-5L). The EQ-5D-5L uses 5 levels (no problems, slight problems, moderate problems, severe problems, and extreme problems) to assess current health status. | Up to 1 year | |
Secondary | Incidence of Adverse Events associated with the interventions | Adverse Events (AEs) will be graded according to Common Terminology Criteria for Adverse Events version 5.0. Comprehensive summaries of all AEs by treatment arm will be generated and examined. Counts and frequencies of worst (highest score) AE per patient will be presented overall and by AE type category, separately by assigned treatment group. The proportion of patients with at least one grade 3 or higher AE will be compared between treatment arm. | Up to 3 years |
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT02224781 -
Dabrafenib and Trametinib Followed by Ipilimumab and Nivolumab or Ipilimumab and Nivolumab Followed by Dabrafenib and Trametinib in Treating Patients With Stage III-IV BRAFV600 Melanoma
|
Phase 3 | |
Active, not recruiting |
NCT05470283 -
Phase I, Open-Label, Study of Tumor Infiltrating Lymphocytes Engineered With Membrane Bound IL15 Plus Acetazolamide in Adult Patients With Metastatic Melanoma
|
Phase 1 | |
Recruiting |
NCT05388877 -
E6201 and Dabrafenib for the Treatment of Central Nervous System Metastases From BRAF V600 Mutated Metastatic Melanoma
|
Phase 1 | |
Active, not recruiting |
NCT05103891 -
Relative Bioavailability of Binimetinib 3 x 15 mg and 45 mg Formulations
|
Phase 1 | |
Completed |
NCT00414765 -
Aldesleukin in Participants With Metastatic Renal Cell Carcinoma or Metastatic Melanoma
|
Phase 4 | |
Completed |
NCT02857270 -
A Study of LY3214996 Administered Alone or in Combination With Other Agents in Participants With Advanced/Metastatic Cancer
|
Phase 1 | |
Completed |
NCT01621490 -
PH 1 Biomarker Study of Nivolumab and Ipilimumab and Nivolumab in Combination With Ipilimumab in Advanced Melanoma
|
Phase 1 | |
Recruiting |
NCT05779423 -
Cryoablation+Ipilimumab+Nivolumab in Melanoma
|
Phase 2 | |
Active, not recruiting |
NCT04940299 -
Tocilizumab, Ipilimumab, and Nivolumab for the Treatment of Advanced Melanoma, Non-Small Cell Lung Cancer, or Urothelial Carcinoma
|
Phase 2 | |
Active, not recruiting |
NCT02278887 -
Study Comparing TIL to Standard Ipilimumab in Patients With Metastatic Melanoma
|
Phase 3 | |
Active, not recruiting |
NCT02360579 -
Study of Lifileucel (LN-144), Autologous Tumor Infiltrating Lymphocytes, in the Treatment of Patients With Metastatic Melanoma
|
Phase 2 | |
Terminated |
NCT02521870 -
A Trial of Intratumoral Injections of SD-101 in Combination With Pembrolizumab in Patients With Metastatic Melanoma or Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
|
Phase 1/Phase 2 | |
Completed |
NCT02177110 -
A Translational Systems Medicine Approach to Provide Predictive Capacity for Therapy Response in Advanced or Metastatic Malignant Melanoma
|
||
Withdrawn |
NCT01340729 -
Open-Label Study of TPI 287 for Patients With Metastatic Melanoma
|
Phase 1/Phase 2 | |
Withdrawn |
NCT01416844 -
Study of Immune Responses in Patients With Metastatic Melanoma
|
Phase 2 | |
Terminated |
NCT01468818 -
Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Melanoma
|
Phase 2 | |
Completed |
NCT00984464 -
Study of REOLYSIN® in Combination With Paclitaxel and Carboplatin in Patients With Metastatic Melanoma
|
Phase 2 | |
Completed |
NCT00631618 -
Clinical Trial of Sutent to Treat Metastatic Melanoma
|
Phase 2 | |
Terminated |
NCT00571116 -
Disulfiram Plus Arsenic Trioxide In Patients With Metastatic Melanoma and at Least One Prior Systemic Therapy
|
Phase 1 | |
Recruiting |
NCT00226473 -
Standard Palliative Care Versus Standard Palliative Care Plus Polychemotherapy in Metastasized Malignant Melanoma
|
Phase 4 |